Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Durvalumab + MEDI9197 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Durvalumab | Imfinzi | MEDI4736 | Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 117 | Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, in combination with Imjudo (tremelimumab) and platinum-based chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) without sensitizing EGFR or ALK mutations, in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer, in combination with cisplatin and gemcitabine in patients with locally advanced or metastatic biliary tract cancer, and in combination with Imjudo (tremelimumab) in adult patients with unresectable hepatocellular carcinoma (FDA.gov). |
MEDI9197 | MEDI-9197|MEDI 9197|Telratolimod|3M-052|3M 052 | TLR7 Agonist 11 TLR8 Agonist 9 | MEDI9197 (telratolimod) acts an an agonist for the TLR7 and TLR8, potentially resulting in increased anti-tumor immune response (J Clin Oncol 34, 2016 (suppl; abstr TPS3095), PMID: 31511088). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02556463 | Phase I | MEDI9197 Durvalumab + MEDI9197 | A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and Palliative Radiation in Subjects With Solid Tumors | Terminated | USA | FRA | CAN | 0 |